{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:00:39Z","timestamp":1792796439951,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.neubiorev.2021.03.028","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T19:46:40Z","timestamp":1617306400000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"special_numbering":"C","title":["The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials"],"prefix":"10.1016","volume":"126","author":[{"given":"Daniel Prates","family":"Baldez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tais Boeira","family":"Biazus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9016-2414","authenticated-orcid":false,"given":"Francisco Diego","family":"Rabelo-da-Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-7983","authenticated-orcid":false,"given":"Guilherme Pedro","family":"Nogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayane Santos","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maur\u00edcio","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-0273","authenticated-orcid":false,"given":"Let\u00edcia Sanguinetti","family":"Czepielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2021.03.028_bib0005","first-page":"14","article-title":"Haloperidol versus risperidone: a comparison of beneficial effect on cognitive function of patients with chronic schizophrenia","volume":"2","author":"Abdolahian","year":"2008","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/appi.ajp.161.2.364","article-title":"Do clozapine and risperidone affect social competence and problem solving?","volume":"161","author":"Bellack","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S1461145705005924","article-title":"Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine","volume":"9","author":"Bender","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0020","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0025","series-title":"Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison","author":"Biondi-Zoccai","year":"2014"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/13546800601069534","article-title":"Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol","volume":"12","author":"Boulay","year":"2007","journal-title":"Cogn. Neuropsychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","article-title":"Cognitive deficits and functional outcome in schizophrenia","volume":"2","author":"Bowie","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0040","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0006-3223(94)90082-5","article-title":"The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance","volume":"36","author":"Buchanan","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0045","series-title":"Schizophrenia Bulletin","first-page":"5","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","author":"Buchanan","year":"2005"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0014-2999(01)01399-1","article-title":"Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine","volume":"430","author":"Bymaster","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000118566","article-title":"Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol","volume":"21","author":"Classen","year":"1989","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0070","series-title":"A Generalized Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials [WWW Document]","author":"Dias","year":"2013"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jrsm.1257","article-title":"Network meta-analysis including treatment by covariate interactions: consistency can vary across covariate values","volume":"8","author":"Donegan","year":"2017","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2105\/AJPH.2018.304677","article-title":"The influence of industry sponsorship on the research agenda: a scoping review","volume":"108","author":"Fabbri","year":"2018","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2007-990291","article-title":"Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol","volume":"40","author":"Gallhofer","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0090","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.4088\/JCP.12m07642","article-title":"BL-1020, a new \u03b3-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study","volume":"73","author":"Geffen","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001504-200201000-00005","article-title":"Recent studies on the neurocognitive effects of second-generation antipsychotic medications","volume":"15","author":"Green","year":"2002","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scog.2014.02.001","article-title":"Cognition in schizophrenia: past, present, and future","volume":"1","author":"Green","year":"2014","journal-title":"Schizophr. Res. Cogn."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0105","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/ajp.154.6.799","article-title":"Does risperidone improve verbal working memory in treatment-resistant schizophrenia?","volume":"154","author":"Green","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0110","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0006-3223(02)01370-7","article-title":"The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone","volume":"51","author":"Green","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0115","article-title":"A systematic review of studies reporting data-driven cognitive subtypes across the psychosis Spectrum","author":"Green","year":"2019","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.euroneuro.2010.08.003","article-title":"Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia","volume":"20","author":"Grootens","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","article-title":"Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment","volume":"158","author":"Harvey","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-9964(98)00109-1","article-title":"Convergence of cognitive and adpatative decline in late-life schizophrenia","volume":"35","author":"Harvey","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00213-002-1342-5","article-title":"Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study","volume":"169","author":"Harvey","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0140","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00213-003-1652-2","article-title":"Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"172","author":"Harvey","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0145","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1176\/appi.ajp.162.10.1888","article-title":"Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial","volume":"162","author":"Harvey","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/jnp.18.1.54","article-title":"Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month","volume":"18","author":"Harvey","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0155","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1176\/ajp.2006.163.11.1918","article-title":"Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning","volume":"163","author":"Harvey","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2007.11.014","article-title":"A randomized double-blind comparison of ziprasidone vs. Clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment","volume":"105","author":"Harvey","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0165","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","article-title":"Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone","volume":"127","author":"Harvey","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0170","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.euroneuro.2013.08.003","article-title":"Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension","volume":"23","author":"Harvey","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00005053-195904000-00008","article-title":"The effects of chlorpromazine upon psychomotor and psychiatric behavior of chronic schizophrenic patients","volume":"128","author":"Heilizer","year":"1959","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0180","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: a quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0185","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br. Med. J."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0190","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","year":"2011"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0195","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1176\/appi.ajp.2013.12101298","article-title":"Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the bipolar- schizophrenia network on intermediate phenotypes (B-SNIP) study","volume":"170","author":"Hill","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0200","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0920-9964(98)00026-7","article-title":"Risperidone versus haloperidol for perception of emotion in treatment- resistant schizophrenia: preliminary findings","volume":"31","author":"Kee","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.schbul.a006990","article-title":"Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale","volume":"29","author":"Keefe","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0220","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0225","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","article-title":"Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol","volume":"161","author":"Keefe","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biopsych.2005.06.022","article-title":"Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis","volume":"59","author":"Keefe","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0240","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0245","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0250","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0006-3223(98)00088-2","article-title":"Risperidone vs. Haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients","volume":"44","author":"Kern","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oxfordjournals.schbul.a033375","article-title":"Risperidone versus haloperidol on secondary memory: can newer medications aid learning?","volume":"25","author":"Kern","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0260","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1176\/appi.ajp.2010.09070937","article-title":"Processing speed deficits in schizophrenia: reexamining the evidence","volume":"167","author":"Knowles","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0265","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3181855cd6","article-title":"Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients","volume":"28","author":"Krakowski","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0270","first-page":"82","article-title":"Effects of clozapine on cognitive function in schizophrenia","volume":"55","author":"Lee","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0275","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2007.03.016","article-title":"Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients","volume":"31","author":"Lee","year":"2007","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0280","series-title":"Neuropsychological Assessment","author":"Lezak","year":"2012"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0285","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(09)60072-6","article-title":"Common genetic influences for schizophrenia and bipolar disorder: a population-based study of 2 million nuclear families","volume":"373","author":"Lichtenstein","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0290","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v68n0303","article-title":"A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia","volume":"68","author":"Lindenmayer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(99)00137-2","article-title":"Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol","volume":"22","author":"Liu","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0300","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/1099-1077(200010)15:7<513::AID-HUP213>3.0.CO;2-Y","article-title":"A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients","volume":"15","author":"Ljubin","year":"2000","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0305","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst. Rev."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0315","first-page":"24","article-title":"The effects of clozapine on cognitive functioning in schizophrenia","volume":"60","author":"McGurk","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1017\/S1092852900005058","article-title":"The effects of risperidone vs haloperidol on cognitive functioning in treatment-resistant schizophrenia: the Trail making Test","volume":"2","author":"McGurk","year":"1997","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-9964(03)00123-3","article-title":"Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia","volume":"68","author":"McGurk","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0330","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1176\/appi.ajp.162.5.1013","article-title":"The effects of clozapine and risperidone on spatial working memory in schizophrenia","volume":"162","author":"McGurk","year":"2005","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0335","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","article-title":"A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"69","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0340","first-page":"55","article-title":"Some memory span functions and motor speed in schizophrenics treated with olanzapine versus fluphenazine","volume":"11","author":"Milas","year":"1999","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0345","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0350","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hup.865","article-title":"Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia","volume":"22","author":"Mortimer","year":"2007","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0355","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia - a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0360","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0365","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/schbul\/sbm053","article-title":"The genetic deconstruction of psychosis","volume":"33","author":"Owen","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2009.08.016","article-title":"The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial","volume":"115","author":"Penn","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0375","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/13803390802592458","article-title":"A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia","volume":"31","author":"Pietrzak","year":"2009","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0380","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"Br. Med. J."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol","volume":"57","author":"Purdon","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0390","first-page":"137","article-title":"Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol","volume":"26","author":"Purdon","year":"2001","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0395","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/JCP.0000000000000078","article-title":"Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder","volume":"34","author":"Rakofsky","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0400","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/wps.20607","article-title":"Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)","volume":"18","author":"Reininghaus","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0405","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2005.07.026","article-title":"The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study","volume":"80","author":"R\u00e9millard","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0410","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1017\/S1355617708080090","article-title":"Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia","volume":"14","author":"R\u00e9millard","year":"2008","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0415","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00406-007-0748-9","article-title":"Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia","volume":"257","author":"Riedel","year":"2007","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0420","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00406-007-0739-x","article-title":"Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms","volume":"257","author":"Riedel","year":"2007","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0425","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.psychres.2010.04.006","article-title":"Antipsychotic medication and social cue recognition in chronic schizophrenia","volume":"178","author":"Roberts","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0430","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia","volume":"290","author":"Rosenheck","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0435","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1176\/appi.ajp.2007.06091515","article-title":"Social cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol","volume":"164","author":"Sergi","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0440","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11065-018-9388-2","article-title":"Cognitive deficits in psychotic disorders: a lifespan perspective","volume":"28","author":"Sheffield","year":"2018","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0445","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S146114570100253X","article-title":"The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia","volume":"4","author":"Smith","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0450","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.schres.2015.08.009","article-title":"Clozapine improves the orienting of attention in schizophrenia","volume":"168","author":"Spagna","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0455","first-page":"583","article-title":"Bayesian measures of model complexity and fit","volume":"54","author":"Spiegel","year":"2002","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0460","series-title":"Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2008"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0465","series-title":"A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary","author":"Strauss","year":"2006"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0470","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0269881105057002","article-title":"The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review","volume":"20","author":"Thornton","year":"2006","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0475","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.schres.2010.04.011","article-title":"Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia","volume":"120","author":"Van Veelen","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0480","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0920-9964(01)00268-7","article-title":"Does cognitive function improve with quetiapine in comparison to haloperidol?","volume":"53","author":"Velligan","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0485","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/schbul\/sbp016","article-title":"Substance use disorders in schizophrenia - clinical implications of comorbidity","volume":"35","author":"Volkow","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0490","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.npp.1300626","article-title":"Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride","volume":"30","author":"Wagner","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0495","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000339456","article-title":"Motor symptoms and schizophrenia","volume":"66","author":"Walther","year":"2012","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0500","doi-asserted-by":"crossref","first-page":"37","DOI":"10.31887\/DCNS.2006.8.1\/bwinklbaur","article-title":"Substance abuse in patients with schizophrenia","volume":"8","author":"Winklbaur","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2021.03.028_bib0505","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763421001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763421001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:58:20Z","timestamp":1758967100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763421001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":101,"alternative-id":["S0149763421001457"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2021.03.028","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2021.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}